Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
You must be a Standard 1 Year member to access this content.